Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1640-1646

  King, Robert W ^a   Klabe, Ronald M ^a   Reid, Carol D ^a   Erickson Viitanen, Susan K ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 CYCLOPROPYLVINYL) 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 4 CYCLOPROPYLETHYNYL 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 CYCLOPROPYLETHYNYL 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REDUCTION; VIRUS REPLICATION;

CELLS, CULTURED; DRUG COMBINATIONS; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NEVIRAPINE; NUCLEOSIDES; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0036090544     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1640-1646.2002     Document Type: Article

References (28)

1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-thiacytidine
2. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS)
3. Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones
4. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro
5. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
6. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors of clinically relevant mutant variants of human immunodeficiency virus type 1
7. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection-a randomized, double-blind, placebo-controlled trial
8. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
9. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor
10. In vivo antagonism with zidovudine plus stavudine combination therapy
11. Intracellular metabolism of zidovudine and stavudine in combination
12. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymdine phosphorylation in vitro
13. Present status and future prospects for HIV therapies
14. In vitro anti-HIV-1 synergy between non-nucleoside reverse transciptase inhibitors nevirapine and efavirenz
15. Triple combinations: Present and future
16. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
17. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
18. Treatment of AIDS with combinations of antiretroviral agents
19. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type I replication in vitro
20. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease
21. In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor
22. Mutations in retroviral genes associated with drug resistance: 1999-2000 Update
23. Synthesis and anti-HIV activity of a series of 2-indolinones and related analogues
24. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1 infected patients
25. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
26. The steady-state pharmacokinetics of efavirenz and vevirapine when used in combination in human immundeficiency virus type-1 infected persons
27. Drug combinations and effect parameters of zidovudine, stavudine and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains